Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Adicet Bio, Inc. is a clinical-stage biotechnology company developing allogeneic "off-the-shelf" gamma delta T cell therapies engineered with chimeric antigen receptors (CARs) for autoimmune diseases and cancer. Its pipeline includes product candidates targeting B cell-mediated autoimmune disorders and CD70+ solid tumors. Adicet’s proprietary platform enables scalable manufacturing from unrelated donors, offering potential advantages in safety, tissue targeting, and cost-efficiency over autologous and other cell therapies.
This description was generated via AI from an annual report. Updated about 1 year ago.